Enoxaparin Versus Unfractionated Heparin in PCI

NCT00439855 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2100

Last updated 2007-02-26

No results posted yet for this study

Summary

Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Conditions

Interventions

DRUG

Enoxaparin i.v.

DRUG

unfractionated heparin

Sponsors & Collaborators

  • Triemli Hospital

    lead OTHER

Principal Investigators

  • osmund bertel, MD · Division of Cardiology Triemli Hospital Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2006-02-28

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439855 on ClinicalTrials.gov